One trading session after Relay Therapeutics (NASDAQ: RLAY) announced positive results for an investigational treatment, its shares rocketed higher on Wednesday. That rally, which saw the biotech ...
Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with ...
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, ...
Relay Therapeutics (NASDAQ:RLAY) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ...
Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.
Stocktwits on MSN
RLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisib
Barclays raised its price target on Relay Therapeutics to $27 from $21 while maintaining an ‘Overweight’ rating, implying a potential upside of 124% from RLAY’s closing price on Tuesday. ・The firm ...
According to a Securities and Exchange Commission (SEC) filing dated Feb. 17, 2026, Nextech Invest, Ltd. bought 855,097 additional shares of Relay Therapeutics (NASDAQ:RLAY). The estimated transaction ...
Relay Therapeutics (RLAY) announced pricing of a public offering of 22.92M shares of its common stock at $12.00 per share. The gross proceeds from this offering are anticipated to be around $275M. The ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Earlier this week, Relay Therapeutics completed a US$275,000,004 follow-on equity offering at US$12.00 per share, shortly after reporting initial Phase 2 ReInspire data showing that zovegalisib led to ...
Relay Therapeutics (NASDAQ:RLAY) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results